BioSpace News Archive

Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a Fireside Chat at the SVB Leerink Global Healthcare Conference, which is scheduled to take place virtually from February 14 – February 18, 2022.

Tiziana Life Sciences Ltd announced that Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

MediWound Ltd. announced that the BARDA part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has expanded its awarded contract with MediWound by providing supplemental funding of $9 million to support the NexoBrid® BLA resubmission with the U.S. Food and Drug Administration and the ongoing expanded access treatment protocol.

Zynerba Pharmaceuticals, Inc. announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET.

IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell Company, today announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle COVID consortium.

Compugen Ltd. announced today that the Company will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 , before the U.S. financial markets open.

Second Genome today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD).

Rocket Pharmaceuticals, Inc. announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET.

AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today reported full-year 2021 financial results for the period ended December 31, 2021.

Respira Labs today announces it has closed $2.8 million to continue to develop and produce its chest wearable that uses acoustic resonance to assess lung function and identify changes in lung air volume, which is especially critical for COPD, COVID-19, and asthma patients.